Kornimate/medical-research-clean huggingface dataset:
the time delay correlated with lv functions and heart failure incidence in stemi?!

Conditions: Myocardial Infarction

Summary: to find out if the time delays between the first medical contacts till the device has an impact on lv functions estimated by transthoracic echocardiography and if it's correlated to heart failure incidence in non-diabetic patients with stemi treated with primary pci


Eligibility criteria:
inclusion criteria: * subjects with anterior stemi according to esc guidelines 2017. * subjects undergoing ppci for the first time . * non diabetic patients. exclusion criteria: * • patients with previous pci. * patients with previous cabg. * patients with timi flow ii or less . * cardiogenic shock.
the art of moving for sustainable health

Conditions: Sedentary Behavior; Stroke

Summary: sedentary behaviour is particularly high among the older and in the presence of a chronic pathology. physical activity is limited mainly by the lack of accessibility to activities offered in the city and the lack of motivation. the objective is to study the physical solicitations and the well-being during the visit of a museum (free or guided visit). our hypothesis is that this cultural activity induces a sufficient physical solicitation for sedentary people and for individuals with a post-stroke motor disability. all the tests will be carried out during the same day by experienced physiotherapists. physical and well-being tests will be performed before and after the visits. the number of steps taken during the visit will be measured. this is a different approach to promote physical activity and this proposal is an original way to stimulate the physical, psychic and social health of sedentary people. if the results are beneficial, museums could become real health partners to stimulate the activity of sedentary people.


Eligibility criteria:
inclusion criteria: * age \> 50 years * sedentary condition (\<150 minutes of physical activity per week) * medical stability * mini mental state evauation \> 22 * walking independently with or without assistance * minibestest \> 20/28 * for individuals with stroke: chronic post-stroke condition. exclusion criteria: * refusal to participate; * person with other conditions affecting independent walking; * contraindications to prolonged standing; * pain greater than 4/10 on the nrs; * concomitant pathologies that may interfere with the results; * inability to follow the study procedure (cognitive disorders, dementia, psychological disorders, language problems...).

Keywords: physical activity museum well-being sedentary stroke
trial of iv injection of cv787 in hormone refractory metastatic prostate cancer

Conditions: Prostate Cancer

Summary: this is a multi-center, open-label, dose finding study of cv787 adenovirus in patients with hormone refractory metastatic prostate cancer. patients will receive treatment intravenously at one of up to nine dose levels, each containing three to six patients.


Eligibility criteria:

Keywords: hormone refractory metastatic prostate cancer
diagnosis of renal cell carcinoma on 68ga-psma pet-ct and radioligand therapy with 177lu-eb-psma-617

Conditions: Renal Cell Carcinoma

Summary: renal cell carcinoma (rcc) is the second most common tumor in urology. considering its origination from kidney, an organ with intense physiological uptake and excretion of 68ga-psma, this study aims to evaluate the uptake of 68ga-psma in rcc compared to 18f-fdg in the same patients, and assess the feasibility of 177lu-eb-psma-617 treatment in patients with the advanced rcc.

renal cell carcinoma (rcc) is the second most common tumor in urology. as one of the popular urinary tumors, the incidence rate increases by 2-4% per year. localized rcc is generally cured by surgery, which has achieved good efficacy. however, advanced rcc are still the main factors influencing the survival of rcc patients due to its intrinsic resistance to conventional chemotherapy or radiotherapy. 18f-fdg pet/ct is considered to be a viable tool to assess rcc at initial presentation. however, fdg uptake in rcc is lower than most other solid tumors and is indistinguishable from benign lesions. so, it is necessary to find another effective way to detect rcc and its metastases. as in known, pro-angiogenic factors (vegf, pdgf) are strongly upregulated in clear cell rcc, leading to high vascularized tumors. 68ga-psma has been developed as a targeting imaging agent widely used in prostate cancer in prostate cancer. thus, this prospective study is going to investigate whether 68ga-psma pet/ct may be superior for diagnosis, therapy response assessment and follow-up of rcc than 18f-fdg pet/ct. furthermore, peptide receptor radionuclide therapy has been widely used in the treatment of prostate cancer lesions that showed high psma uptake on 68ga-psma pet/ct, we'll try to assess the safety and therapeutic response to 177lu-eb-psma-617 in patients with rcc.

Eligibility criteria:
inclusion criteria: * confirmed treated or untreated renal cell carcinoma patients; * 68ga-psma pet/ct and 18f-fdg pet/ct within two weeks; * signed written consent. exclusion criteria: * pregnancy; * breastfeeding; * known allergy against psma * any medical condition that in the opinion of the investigator may significantly interfere with study compliance
dose ranging study of combined haemophilus influenzae type b-meningococcal serogroups cy (hib-mency-tt) vaccine

Conditions: Haemophilus Influenzae Type b; Neisseria Meningitidis

Summary: this study evaluated the safety and immunogenicity of 3 formulations of hib-mency-tt vaccine compared to 2 control groups receiving licensed meningococcal serogroup c conjugate vaccine and/or licensed hib conjugate vaccine administered at 2, 4, and 6 months of age. antibody persistence and immune responses to polysaccharide vaccine boosters were additionally assessed at 11 to 14 months of age.


Eligibility criteria:
inclusion criteria: * a male or female between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination. * written informed consent obtained from the parent or guardian of the subject. * free of obvious health problems as established by medical history and clinical examination before entering into the study. * vaccinated against hepatitis b at birth. * born after a gestation period of 36 - 42 weeks. exclusion criteria: * use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * chronic administration of immunosuppressants or other immune-modifying drugs since birth * any chronic drug therapy to be continued during the study period. * planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the first dose of vaccine(s). * previous vaccination against diphtheria, tetanus, pertussis, polio, n. meningitidis of serogroups c and y, haemophilus influenzae type b or streptococcus pneumoniae. * history of or known exposure to diphtheria, tetanus, pertussis, polio, or invasive diseases due to n. meningitidis of serogroups c and y, haemophilus influenzae type b or streptococcus pneumoniae. * any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection. * a family history of congenital or hereditary immunodeficiency. * history of allergic disease or reactions likely to be exacerbated by any component of the vaccines. * major congenital defects or serious chronic illness. * history of any neurologic disorders or seizures. * acute disease at the time of enrolment. * administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

Keywords: invasive bacterial disease caused by hib neisseria meningitidis serogroups c & y
a detailed look at what patients experience when they take part in hypertension clinical trials

Conditions: Hypertension

Summary: this research study aims to identify the obstacles faced by specific demographic groups of hypertension patients during their engagement in clinical trials. the study will collect in-depth information from participants and identify common factors that impede their enrollment or successful completion of these trials. by examining data from various demographic perspectives, the study aims to identify patterns impacting future hypertension patients' experiences.


Eligibility criteria:
inclusion criteria: * patient is at least 18 years of age * diagnosis of hypertension * ability to understand the study procedures, benefits and risks, and sign a written informed consent document. exclusion criteria: * enrolled in another research study * inability to provide written informed consent * women of childbearing potential without a negative pregnancy test; or women who are lactating.

Keywords: hypertension
impact of socio-aesthetic care in the quality of life of patients treated for lymphoma during and after hospitalization

Conditions: Lymphoma

Summary: in the early 2000s , professional and patient organizations are mobilizing to highlight the psychosocial impact of cancer disease , not only during but also after the acute phase. in 2003, the government launched the cancer plan i reinforced in december 2011 by the cancer plan ii whose objectives include : " develop a personalized care taking into account the pain and psychological and social support " and " increase opportunities for patients to benefit from supportive care "and" promote the professional integration . this study aims to show that beyond the immediate benefits of the social aesthetic cares in hospital (direct soothing, improving the quality of the skin injured by chemotherapy , feeling of escape ... ), these treatments can also affect quality of life for patients during and after hospitalization. they also may have an impact on the maintenance of social and / or professional satisfactory throughout the planned chemotherapy aplastic period .


Eligibility criteria:
inclusion criteria: * 18 to 65 years old * hospitalized in the hematology care unit in uh angers * initial hodgkin lymphoma, diffuse large b-cell lymphoma and mantle cell lymphoma * without previous socio-aesthetic care. exclusion criteria: * age \<18 years old. * patient protected by the law. * patient at end of life. * patient unable to respond to the questionnaire. * previous socio aesthetic care.
comparison of two nn5401 formulations versus insulin glargine, all in combination with metformin in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this trial is to compare two nn5401 (siac, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any trial-related activities. (trial-related activities are any procedure that would not have been performed during normal management of the subject.) * insulin naïve type 2 diabetes subjects (as diagnosed clinically) for at least 3 months (no previous insulin treatment or previous short term insulin treatment maximum 14 days within the last 3 months) * treatment with one or two oral anti-diabetic drugs (oads): metformin, sulfonylurea, other insulin secretagogue (e.g. repaglinide, nateglinide), alpha-glucosidase inhibitors for at least 2 month at a stable maximum tolerated dose or at least half maximum allowed dose according to locally approved summary of product characteristics (spc) * hba1c, 7.0 - 11.0 % (both inclusive) * body mass index (bmi), 25.0 - 37.0 kg/m\^2 (both inclusive) exclusion criteria: * metformin contraindication according to local practice * thiazolidinedione (tzd) treatments within the previous three months prior to visit 1 * any systemic treatment with products, which in the investigator's opinion could interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) within 3 months prior to randomisation * subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system that, in the opinion of the investigator, may confound the results of the trial or pose additional risk in administering trial product
blood and cerebrospinal fluid metabolomic profile in glioma patients

Conditions: Glioma; Glioblastoma Multiforme

Summary: this is an exploratory, non-interventional and translational clinical study. the aim of this study is to analyze blood and cerebrospinal fluid metabolomic profile in glioma patients.

the analysis of metabolic profile in the plasma and csf could become the new less invasive approach in the establishing diagnosis as well as an important prognostic factor in patients with glioma. the researches will assess the blood and csf metabolic profile in patients with different types of gliomas as well as in patient without ones. this can help to find new biomarkers for low- and high-grade gliomas correlating with patient outcomes. blood and csf samples will be collected from patients with suspected newly diagnosed low-grade (i-ii) or high-grade (iii-iv) gliomas as well as from patients who have hospitalized for reconstructive surgery after craniofacial trauma. all samples will be collected before any surgical intervention and at various follow-up time points until progression or death. the results of the study are planned to be translated into the hospital setting as support to other diagnostics procedures and to the differential diagnosis between glioma grades.

Eligibility criteria:
inclusion criteria: 1. all patients with suspected newly diagnosed glioma (grade i, ii, iii or glioblastoma) with planned surgical intervention (resection or biopsy). 2. patient aged 18 years or older 3. patients have to be able to give informed consent exclusion criteria: 1. prior radiotherapy to the central nervous system 2. prior chemotherapy within the last 5 years 3. any prior central nervous system malignancy 4. any surgery during last 6 month

Keywords: metabolomic profile biomarkers
palbociclib / letrozole or fulvestrant in african american women with hr+ her2- breast cancer

Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer

Summary: this study aims to evaluate the hematological safety of palbociclib with letrozole and fulvestrant in african american women with hormone receptor positive her2 negative advanced breast cancer. hematological safety is a composite endpoint of episodes of febrile neutropenia and treatment discontinuation due to neutropenia according to current recommendations for management of neutropenia

the study is designed to assess the rate of completion of planned oncology therapy in the absence of a hematological event defined as episodes of febrile neutropenia and treatment discontinuation due to neutropenia. a completion rate of 80% is considered of clinical relevance as to benefit breast cancer patients who are at a higher risk of having ethnic neutropenia where as a completion rate of 60% is considered poor and to justify additional safety studies. a two stage design with a total of 35 patients is used to test if the completion rate is at least 80% versus if it is below 60% with 80% power at a significance level of 5%. an exact confidence interval of the completion rate will be calculated. investigators estimate there will be no more than a 10% rate of febrile neutropenia. due to the small sample size, the analysis of secondary endpoints will be descriptive and will not include specific hypothesis testing.

Eligibility criteria:
inclusion criteria: 1. self-identified black, african or african american women of ≥ 18 years of age with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease) 2. er-positive and/or pgr-positive tumor based on local laboratory results 3. her2-negative breast cancer based on local laboratory results (test to be used as per local practice) 4. patients must be appropriate candidates for letrozole or fulvestrant therapy 5. eastern cooperative oncology group (ecog) performance status 0-2 6. adequate bone marrow function: * absolute neutrophil count (anc) ≥ 1,000/mm3 (1.0 x 109/l); * platelets ≥100,000/mm3 (100 x 109/l); * hemoglobin ≥9 g/dl (90 g/l). exclusion criteria: 1. current use of food or drugs known to be potent inhibitors or inducers of cyp3a4 2. active uncontrolled or symptomatic brain metastases. previously treated and clinically stable, as per investigator's judgment, brain metastases are permitted. 3. previous cdk4/6 inhibitor -

Keywords: african american
the effectiveness of 3rd occipital radiofrequency versus systemic steroid in headache management in rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Headache

Summary: rheumatoid arthritis is a common type of autoimmune arthritis that is characterized by inflammation of the synovial membranes. even though any joint can be affected by the disease, cervical spine is often affected, and cervical pain is reported by 40-88% of ra patients, cervical spine involvement is a feature of long-lasting disease, where atlantoaxial impaction with odontoid process vertical subluxation through the foramen magnum being one of the greatest and dangerous complications

to our knowledge the effectiveness of 3rd occipital nerve blocks in managing chronic upper neck pain, headache in ra patients is not measured yet, so we aimed at assessing the the effectiveness of 3rd occipital nerve blocks in headache management in ra patients who used other medical agents and to compare the results with those of the patients who used only 3rd occipital nerve pulsed radiofrequancy on clinical and radiographic bases.

Eligibility criteria:
inclusion criteria: * patients suffering from upper neck pain and/or headache due to bilateral 3rd occipital nerve involvement evidenced by magnetic resonance imaging (mri). exclusion criteria: * disc herniation with radicular pain, * symptomatic spinal stenosis, * surgical interventions of the cervical spine within the last 3 months, * uncontrolled major depression or psychiatric disorders, * heavy opioid usage
fluid retention in rosiglitazone treated subjects with autonomic neuropathy.

Conditions: Neuropathy, Diabetic

Summary: fluid management study in patients with type 2 diabetes and autonomic neuropathy.


Eligibility criteria:
inclusion criteria: * subjects with type 2 diabetes (t2dm) as defined by the 1999 who criteria \[world health organisation , 1988/ncd/ncs/99.2\] with stable fpg of = 7.0 and = 15.0 mmol/l who have been established on insulin therapy for at least 6 months * bmi = 40 kg.m2 * subject who is willing and able to provide a signed and dated written informed consent. exclusion criteria: * subjects with an hba1c level \> 12% * subjects taking oral hypoglycaemic agents other than metformin * subjects on insulin dosage \> 200 units/day

Keywords: fluid retention autonomic neuropathy
deep brain stimulation for treatment resistant depression

Conditions: Depressive Disorder, Major

Summary: this study will investigate the safety and efficacy of deep brain stimulation (dbs) in lateral habenula (lh) for patients with treatment-resistant depression.


Eligibility criteria:
inclusion criteria: 1. age 18-70, regardless of gender; 2. diagnostic and statistical manual of mental disorders 5th ed (dsm-v), for psychiatrists' examination of severe depressive disorders; 3. same diagnostic conclusions based on dsm-v made by two independent psychiatrists; 4. a minimum of 24 months of depressive history, over 2 or more adequate antidepressant trials with hamilton depression rating scale (hamd) reduction rate ≤20% (including mect) ; 5. hamd-17 scores ⩾ 20 at screening; 6. functional general assessment table (gaf) rating ≤50; 7. able to comply with the operational and administrative requirements of participation in the study, and able to give written informed consent. exclusion criteria: 1. patients with severe or unstable mental, liver, kidney, endocrine, hematological diseases, or those with psychotic co-morbidities, including personality disorders; 2. history of substance abuse in the past 12 months; history of epilepsy, or febrile seizure in childhood; 3. patients who have attempted suicide within the past 6 months, or have had a secondary suicide attempt within the past 2 years; 4. women who are breastfeeding, pregnant, or intend to be pregnant during the clinical study; 5. any surgical contraindications to undergoing deep brain stimulation (dbs); 6. patients who cannot give full informed consent.

Keywords: deep brain stimulation lateral habenula
compliance with the european society of cardiology prevention guidelines in patients at high cardiovascular disease risk

Conditions: Hypertension; Diabetes; Dyslipidemias

Summary: patients with coronary or other atherosclerotic cardiovascular disease and those at high risk of developing cardiovascular disease have been defined as the highest clinical priorities for prevention

cardiovascular disease prevention programs are designed to reduce patients' morbidity and mortality.the european society of cardiology with other partner societies has engaged in a comprehensive programme of cardiovascular disease prevention in clinical practice aimed to improve practice of preventive cardiology by encouraging the development of national guidance on cardiovascular disease prevention

Eligibility criteria:
inclusion criteria: * patients having signed an informed consent patients aged from 18 to 80 years old at the time of identification at least six and at most 24 months elapsed between the index event (the recruiting diagnostic or treatment criteria below) and the date of interview patients meeting the recruiting diagnostic or treatment criteria: high cvd risk patients: patients free of cvd, who have been prescribed one or more of the following treatments: blood pressure and/or lipid-lowering and/or glucose lowering (diet and/or oral hypoglycaemic agents) exclusion criteria: * patients living outside defined geographical area (assiut governorate)
baseline cardiovascular measurements in pediatric spinal cord injury

Conditions: Spinal Cord Injury

Summary: following spinal cord injury (sci), the body loses normal control of blood pressure and heart rate, and there is a risk of sudden and dangerous increases in blood pressure, namely, autonomic dysreflexia (ad). it is important to be aware of baseline blood pressures and heart rates in individuals in order to detect ad. however, baseline values vary in developing children, and may be more variable in children with sci. thus, the objective of this study is to determine baseline blood pressure and heart rate measurements in children with sci during rest and during urodynamic testing. the investigators hypothesize that 1) blood pressures will increase with increasing age and body mass index; 2) heart rate will decrease with increasing age; 3) blood pressures will increase with increase in bladder filling; 4) blood pressures will increase will increase with increasing duration of injury.


Eligibility criteria:
inclusion criteria: * children and adolescents with spinal cord injury * age 18 years or younger exclusion criteria: * known history of hypertension, cardiac, renal, or thyroid disease * recent surgical procedure less than 2 weeks prior to admission or visit * fever or signs of active infection or inflammation

Keywords: pediatric spinal cord injury blood pressure heart rate baseline